[{"address1": "601 Brickell Key Drive", "address2": "Suite 1000", "city": "Miami", "state": "FL", "zip": "33131", "country": "United States", "phone": "650 460 8308", "website": "https://www.summittxinc.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.", "fullTimeEmployees": 105, "auditRisk": 6, "boardRisk": 8, "compensationRisk": 10, "shareHolderRightsRisk": 5, "overallRisk": 10, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 2, "previousClose": 7.8, "open": 7.79, "dayLow": 7.71, "dayHigh": 8.15, "regularMarketPreviousClose": 7.8, "regularMarketOpen": 7.79, "regularMarketDayLow": 7.71, "regularMarketDayHigh": 8.15, "beta": -1.027, "trailingPE": 20.868422, "forwardPE": -27.344828, "volume": 8348134, "regularMarketVolume": 8348134, "averageVolume": 4104550, "averageVolume10days": 3324610, "averageDailyVolume10Day": 3324610, "bid": 7.91, "ask": 7.96, "bidSize": 600, "askSize": 500, "marketCap": 5566701568, "fiftyTwoWeekLow": 1.52, "fiftyTwoWeekHigh": 11.25, "fiftyDayAverage": 5.391, "twoHundredDayAverage": 3.525975, "currency": "USD", "enterpriseValue": 5519540224, "floatShares": 73335808, "sharesOutstanding": 701980032, "sharesShort": 22565474, "sharesShortPriorMonth": 22896771, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0321, "heldPercentInsiders": 0.88144, "heldPercentInstitutions": 0.07229, "shortRatio": 11.39, "shortPercentOfFloat": 0.2708, "impliedSharesOutstanding": 701980032, "bookValue": 0.063, "priceToBook": 125.87301, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -116025000, "trailingEps": 0.38, "forwardEps": -0.29, "enterpriseToEbitda": -48.101, "52WeekChange": 2.2105262, "SandP52WeekChange": 0.26238096, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "SMMT", "underlyingSymbol": "SMMT", "shortName": "Summit Therapeutics Inc.", "longName": "Summit Therapeutics Inc.", "firstTradeDateEpochUtc": 1425565800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d8568743-2bb7-3bc5-b04d-4193fee0ce0a", "messageBoardId": "finmb_11611587", "gmtOffSetMilliseconds": -14400000, "currentPrice": 7.93, "targetHighPrice": 14.0, "targetLowPrice": 5.0, "targetMeanPrice": 10.67, "targetMedianPrice": 13.0, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 156680000, "totalCashPerShare": 0.223, "ebitda": -114750000, "totalDebt": 109522000, "quickRatio": 6.725, "currentRatio": 6.966, "debtToEquity": 247.731, "returnOnAssets": -0.33266997, "returnOnEquity": -1.30591, "freeCashflow": -527605504, "operatingCashflow": -93763000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]